Ferric maltol - Shield Therapeutics

Drug Profile

Ferric maltol - Shield Therapeutics

Alternative Names: Feraccru; Iron (III) maltol; ST-10; ST10-021

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Cambridge; University of London
  • Developer Shield Therapeutics
  • Class Antianaemics; Ferric compounds; Pyrones; Small molecules
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia

Most Recent Events

  • 26 Apr 2018 Shield Therapeutics initiates phase III clinical trial in Iron deficiency anaemia (in patients with pulmonary hypertension) in Germany (NCT03371173) (EudraCT 2016-005100-26)
  • 06 Apr 2018 Ferric maltol - Shield Therapeutics is available for licensing in Europe and USA as of 06 Apr 2018. https://www.shieldtherapeutics.com/
  • 06 Apr 2018 Shield Therapeutics plans to file an NDA to US FDA for Iron deficiency anaemia by the end of June 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top